WIM
Woodford Investment Management Portfolio holdings
AUM
$310M
This Quarter Return
-14.44%
1 Year Return
-17.41%
3 Year Return
-27.69%
5 Year Return
+67.02%
10 Year Return
–
AUM
$591M
AUM Growth
+$591M
(-52%)
Cap. Flow
-$374M
Cap. Flow
% of AUM
-63.27%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
1
Reduced
4
Closed
3
Top Buys
| 1 |
EVFM
Evofem Biosciences, Inc. Common Stock
EVFM
|
$14.5M |
Top Sells
| 1 |
Agios Pharmaceuticals
AGIO
|
$149M |
| 2 |
Alkermes
ALKS
|
$96.3M |
| 3 |
Biogen
BIIB
|
$70.9M |
| 4 |
Prothena Corp
PRTA
|
$33.3M |
| 5 |
Theravance Biopharma
TBPH
|
$19.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Theravance Biopharma
TBPH
$699M
| $199M | 33.59% | 12,159,980 -1,219,999 | -9% | -$19.9M |
|
|
AUTL
2
Autolus Therapeutics
AUTL
$399M
| $187M | 31.58% | 11,594,234 -447,185 | -4% | -$7.2M |
|
|
3
Prothena Corp
PRTA
$441M
| $92.7M | 15.69% | 8,773,790 -3,150,824 | -26% | -$33.3M |
|
|
EVFM
4
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
| $91.2M | 15.43% | 13,733,835 +2,190,107 | +19% | +$14.5M |
|
|
NCNA
5
NuCana
NCNA
$6.09M
| $22M | 3.72% | 2,118,000 -1,112,999 | -34% | -$11.6M |
|
|
6
Agios Pharmaceuticals
AGIO
$2.19B
| – | – | -2,214,459 | Closed | -$149M |
|
|
7
Alkermes
ALKS
$4.78B
| – | – | -2,639,676 | Closed | -$96.3M |
|
|
8
Biogen
BIIB
$19.4B
| – | – | -300,040 | Closed | -$70.9M |
|